发明名称 COMPOUND FOR TREATMENT OF METABOLIC DISTURBANCE
摘要 <p><P>PROBLEM TO BE SOLVED: To provide useful compounds for treatments of various metabolic disturbances (for example, insulin resistant syndromes, diabetes mellitus, hyperlipidemia, fatty liver diseases, cachexia, obesity, atherosclerosis and arterial sclerosis). <P>SOLUTION: Biologically active drugs, namely the drugs are compounds shown by formula I or their pharmaceutically acceptable salts, wherein n represents 1 or 2, m represents 0 or 1, q represents 0 or 1, t represents 0 or 1, R<SP>9</SP>represents a hydrogen, a halogen or 1-3C alkoxy, X represents -CH<SB>2</SB>- and Q represents -OR<SP>1</SP>, or X represents -CH<SB>2</SB>CR<SP>12</SP>CR<SP>13</SP>- or -CH<SB>2</SB>CH(NHAc)- and Q represents -OR<SP>1</SP>, or X represents -CH<SB>2</SB>CH<SB>2</SB>- and Q represents NR<SP>10</SP>R<SP>11</SP>. <P>COPYRIGHT: (C)2010,JPO&INPIT</p>
申请公布号 JP2009221232(A) 申请公布日期 2009.10.01
申请号 JP20090161270 申请日期 2009.07.07
申请人 WELLSTAT THERAPEUTICS CORP 发明人 SHARMA SHALINI;VON BORSTEL REID W;HODGE KIRVIN L;BAMAT MICHAEL K;WOLPE STEPHEN D
分类号 A61K31/00;A61K31/192;A61K31/16;A61K31/165;A61K31/198;A61K31/216;A61K31/235;A61K31/27;A61K31/381;A61K31/41;A61K31/4196;A61K31/4402;A61K31/445;A61K31/535;A61K31/54;A61P1/16;A61P3/04;A61P3/06;A61P3/10;A61P7/00;A61P9/10;A61P9/12;A61P13/12;A61P17/02;A61P25/00;A61P27/02;A61P27/12;A61P35/00;C07C59/54;C07C59/68;C07C59/90;C07C69/738;C07C217/22;C07C233/47;C07C235/34;C07C235/78;C07C235/84;C07C237/32;C07C259/06;C07C323/47;C07C323/52;C07C323/59;C07C323/60;C07D213/30;C07D213/55;C07D249/10;C07D249/12;C07D257/04;C07D333/16;C07D333/18;C07D333/22 主分类号 A61K31/00
代理机构 代理人
主权项
地址